Indonesian Journal of Cancer
Vol 16, No 4 (2022): December

CD4+ and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Biomarkers: Role in Predicting the Stadium and Prognosis of Cervical Cancer

Humairah Medina Liza Lubis (Department of Anatomical Pathology, Faculty of Medicine, Universitas Muhammadiyah Sumatera Utara, Medan, Sumatera Utara)
Rafa Nabila Haifa (Faculty of Medicine, Universitas Muhammadiyah Sumatera Utara, Medan, Sumatera Utara)
Rizky Yusfasari (Faculty of Medicine, Universitas Muhammadiyah Sumatera Utara, Medan, Sumatera Utara)
Muhammad Zikri Agung Ramadhan (Faculty of Medicine, Universitas Muhammadiyah Sumatera Utara, Medan, Sumatera Utara)



Article Info

Publish Date
28 Dec 2022

Abstract

Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.

Copyrights © 2022






Journal Info

Abbrev

ijoc

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Description

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical ...